Download PDF
Clin Colon Rectal Surg 2023; 36(06): 369-377
DOI: 10.1055/s-0043-1767706
Review Article

Screening and Management of Lynch Syndrome: The Chinese Experience

Jiehai Yu
1   Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, P. R. China
,
Pei-Rong Ding
1   Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, P. R. China
,
Wu Jiang
1   Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou Guangdong, P. R. China
› Author Affiliations Funding This study was funded by the National Natural Science Foundation of China (grant numbers 82073159 and 81871971) and Guangdong Basic and Applied Basic Research Foundation (2022A1515012403).
› Further Information
   Permissions and Reprints

Abstract

Lynch syndrome (LS), caused by germline mutations in the mismatch repair genes, is the most common hereditary colorectal cancer. While LS is also associated with various cancers, early detection of the proband is meaningful for tumor prevention, treatment, and familial management. It has been a dramatic shift on the screening approaches for LS. As the rapid development of the molecular biological methods, a comprehensive understanding of the LS screening strategies will help to improve the clinical care for this systematic disease. The current screening strategies have been well validated but mainly by evidence derived from western population, lacking consideration of the ethnic heterogeneity, which hampers the universality and clinical application in China. Hence, this review will focus on the Chinese experience in LS screening, aiming to help better understand the ethnic diversity and further optimize the screening strategies.

Keywords

colorectal cancer - Lynch syndrome - universal screening - ethnic heterogeneity


Publication History

Article published online:
03 May 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Yurgelun MB, Kulke MH, Fuchs CS. et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 2017; 35 (10) 1086-1095
    CrossrefPubMedGoogle Scholar
  • 2 Jiang W, Li L, Ke CF. et al. Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. J Med Genet 2022; 59 (04) 370-376
    CrossrefPubMedGoogle Scholar
  • 3 Aaltonen LA, Salovaara R, Kristo P. et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998; 338 (21) 1481-1487
    CrossrefPubMedGoogle Scholar
  • 4 Hampel H, Frankel WL, Martin E. et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352 (18) 1851-1860
    CrossrefPubMedGoogle Scholar
  • 5 Moreira L, Balaguer F, Lindor N. et al; EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308 (15) 1555-1565
    Google Scholar
  • 6 Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 2013; 31 (20) 2554-2562
    CrossrefPubMedGoogle Scholar
  • 7 Win AK, Young JP, Lindor NM. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30 (09) 958-964
    CrossrefPubMedGoogle Scholar
  • 8 Bonadona V, Bonaïti B, Olschwang S. et al; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305 (22) 2304-2310
    Google Scholar
  • 9 Watson P, Vasen HFA, Mecklin JP. et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008; 123 (02) 444-449
    CrossrefPubMedGoogle Scholar
  • 10 Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116 (06) 1453-1456
    CrossrefPubMedGoogle Scholar
  • 11 Rodriguez-Bigas MA, Boland CR, Hamilton SR. et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89 (23) 1758-1762
    CrossrefPubMedGoogle Scholar
  • 12 Umar A, Boland CR, Terdiman JP. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96 (04) 261-268
    CrossrefPubMedGoogle Scholar
  • 13 Shia J. The diversity of tumours with microsatellite instability: molecular mechanisms and impact upon microsatellite instability testing and mismatch repair protein immunohistochemistry. Histopathology 2021; 78 (04) 485-497
    CrossrefPubMedGoogle Scholar
  • 14 Win AK, Jenkins MA, Dowty JG. et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev 2017; 26 (03) 404-412
    CrossrefPubMedGoogle Scholar
  • 15 Goodenberger ML, Thomas BC, Riegert-Johnson D. et al. PMS2 monoallelic mutation carriers: the known unknown. Genet Med 2016; 18 (01) 13-19
    CrossrefPubMedGoogle Scholar
  • 16 ten Broeke SW, Brohet RM, Tops CM. et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol 2015; 33 (04) 319-325
    CrossrefPubMedGoogle Scholar
  • 17 Ryan NAJ, Morris J, Green K. et al. Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 2017; 3 (12) 1702-1706
    CrossrefPubMedGoogle Scholar
  • 18 Salovaara R, Loukola A, Kristo P. et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000; 18 (11) 2193-2200
    CrossrefPubMedGoogle Scholar
  • 19 Hampel H, Frankel WL, Martin E. et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26 (35) 5783-5788
    CrossrefPubMedGoogle Scholar
  • 20 Pérez-Carbonell L, Ruiz-Ponte C, Guarinos C. et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012; 61 (06) 865-872
    CrossrefPubMedGoogle Scholar
  • 21 Jiang W, Cai MY, Li SY. et al; Written on behalf of AME Colorectal Cancer Cooperative Group. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer 2019; 144 (09) 2161-2168
    CrossrefPubMedGoogle Scholar
  • 22 Yang M, Li D, Jiang W. et al. Development and external validation of a novel nomogram for screening Chinese Lynch syndrome: based on a multicenter, population study. Ther Adv Med Oncol 2021;13(Jun):17588359211023290
    PubMedGoogle Scholar
  • 23 Vasen HF. Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. [hereditary nonpolyposis colorectal cancer (HNPCC)] Fam Cancer 2005; 4 (03) 219-225
    CrossrefPubMedGoogle Scholar
  • 24 Perea J, Rodríguez Y, Rueda D. et al. Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. Ann Surg Oncol 2011; 18 (12) 3285-3291
    CrossrefPubMedGoogle Scholar
  • 25 Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110 (02) 223-262 , quiz 263
    CrossrefPubMedGoogle Scholar
  • 26 Giardiello FM, Allen JI, Axilbund JE. et al; US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2014; 147 (02) 502-526
    CrossrefPubMedGoogle Scholar
  • 27 de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P. et al. Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 2003; 52 (12) 1752-1755
    CrossrefPubMedGoogle Scholar
  • 28 Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995; 345 (8958): 1183-1184
    CrossrefPubMedGoogle Scholar
  • 29 Jenkins MA, Hayashi S, O'Shea AM. et al; Colon Cancer Family Registry. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007; 133 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 30 Bessa X, Alenda C, Paya A. et al. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. J Clin Oncol 2011; 29 (25) 3374-3380
    CrossrefPubMedGoogle Scholar
  • 31 Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34 (05) 424-425
    CrossrefPubMedGoogle Scholar
  • 32 Barnetson RA, Tenesa A, Farrington SM. et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354 (26) 2751-2763
    CrossrefPubMedGoogle Scholar
  • 33 Yuan Y, Han HJ, Zheng S, Park JG. Germline mutations of hMLH1 and hMSH2 genes in patients with suspected hereditary nonpolyposis colorectal cancer and sporadic early-onset colorectal cancer. Dis Colon Rectum 1998; 41 (04) 434-440
    CrossrefPubMedGoogle Scholar
  • 34 Yuan Y, Ye J, Zheng S. International Collaborative Group. Clinical and genetic features of International Collaborative Group-hereditary nonpolyposis colorectal cancer families and suspected hereditary nonpolyposis colorectal cancer families. Chin Med J (Engl) 2004; 117 (05) 748-752
    PubMedGoogle Scholar
  • 35 Chen S, Wang W, Lee S. et al; Colon Cancer Family Registry. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296 (12) 1479-1487
    CrossrefPubMedGoogle Scholar
  • 36 Kastrinos F, Steyerberg EW, Balmaña J. et al; Colon Cancer Family Registry. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut 2013; 62 (02) 272-279
    CrossrefPubMedGoogle Scholar
  • 37 Green RC, Parfrey PS, Woods MO, Younghusband HB. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. J Natl Cancer Inst 2009; 101 (05) 331-340
    CrossrefPubMedGoogle Scholar
  • 38 Kastrinos F, Ojha RP, Leenen C. et al; Lynch Syndrome prediction model validation study group. Comparison of prediction models for Lynch syndrome among individuals with colorectal cancer. J Natl Cancer Inst 2015; 108 (02) djv308
    PubMedGoogle Scholar
  • 39 Adar T, Rodgers LH, Shannon KM. et al. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer 2018; 124 (15) 3145-3153
    CrossrefPubMedGoogle Scholar
  • 40 Heald B, Plesec T, Liu X. et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 2013; 31 (10) 1336-1340
    CrossrefPubMedGoogle Scholar
  • 41 Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10 (04) 293-300
    CrossrefPubMedGoogle Scholar
  • 42 Zhang L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10 (04) 301-307
    CrossrefPubMedGoogle Scholar
  • 43 Cohen SA, Pritchard CC, Jarvik GP. Lynch syndrome: from screening to diagnosis to treatment in the era of modern molecular oncology. Annu Rev Genomics Hum Genet 2019; 20: 293-307
    CrossrefPubMedGoogle Scholar
  • 44 Chika N, Eguchi H, Kumamoto K. et al. Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol 2017; 47 (02) 108-117
    CrossrefPubMedGoogle Scholar
  • 45 Xiao B, Luo J, Xie E. et al. Comparisons of screening strategies for identifying Lynch syndrome among patients with MLH1-deficient colorectal cancer. Eur J Hum Genet 2020; 28 (11) 1555-1562
    CrossrefPubMedGoogle Scholar
  • 46 Adar T, Rodgers LH, Shannon KM. et al. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. Mod Pathol 2017; 30 (03) 440-447
    CrossrefPubMedGoogle Scholar
  • 47 Moreira L, Muñoz J, Cuatrecasas M. et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer. Cancer 2015; 121 (09) 1395-1404
    CrossrefPubMedGoogle Scholar
  • 48 Jiang Y, Yang M, Wang S, Li X, Sun Y. Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer Commun (Lond) 2020; 40 (04) 154-166
    CrossrefPubMedGoogle Scholar
  • 49 Mori Y, Bretthauer M, Kalager M. Hopes and hypes for artificial intelligence in colorectal cancer screening. Gastroenterology 2021; 161 (03) 774-777
    CrossrefPubMedGoogle Scholar
  • 50 Jiang W, Mei WJ, Xu SY. et al. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning. EBioMedicine 2022; 81 (Jul): 104120
    CrossrefPubMedGoogle Scholar
  • 51 Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009; 11 (01) 35-41
    CrossrefPubMedGoogle Scholar
  • 52 Benson AB, Venook AP, Al-Hawary MM. et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw 2018; 16 (04) 359-369
    CrossrefPubMedGoogle Scholar
  • 53 Niu B, Ye K, Zhang Q. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 2014; 30 (07) 1015-1016
    CrossrefPubMedGoogle Scholar
  • 54 Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014; 60 (09) 1192-1199
    CrossrefPubMedGoogle Scholar
  • 55 Zhu L, Huang Y, Fang X. et al. A novel and reliable method to detect microsatellite instability in colorectal cancer by next-generation sequencing. J Mol Diagn 2018; 20 (02) 225-231
    CrossrefPubMedGoogle Scholar
  • 56 Jiang W, Sui QQ, Li WL. et al. Low prevalence of mismatch repair deficiency in Chinese colorectal cancers: a multicenter study. Gastroenterol Rep (Oxf) 2020; 8 (05) 399-403
    CrossrefPubMedGoogle Scholar
  • 57 Kallenberg FG, IJspeert JE, Bossuyt PM, Aalfs CM, Dekker E. Validation of an online questionnaire for identifying people at risk of familial and hereditary colorectal cancer. Fam Cancer 2015; 14 (03) 401-410
    CrossrefPubMedGoogle Scholar
  • 58 Kallenberg FGJ, Aalfs CM, The FO. et al. Evaluation of an online family history tool for identifying hereditary and familial colorectal cancer. Fam Cancer 2018; 17 (03) 371-380
    CrossrefPubMedGoogle Scholar
  • 59 Korhonen MK, Vuorenmaa E, Nyström M. The first functional study of MLH3 mutations found in cancer patients. Genes Chromosomes Cancer 2008; 47 (09) 803-809
    CrossrefPubMedGoogle Scholar
  • 60 Chen PC, Dudley S, Hagen W. et al. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res 2005; 65 (19) 8662-8670
    CrossrefPubMedGoogle Scholar
  • 61 Chen PC, Kuraguchi M, Velasquez J. et al. Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. PLoS Genet 2008; 4 (06) e1000092
    CrossrefPubMedGoogle Scholar
  • 62 Sui QQ, Jiang W, Wu XD, Ling YH, Pan ZZ, Ding PR. A frameshift mutation in exon 19 of MLH1 in a Chinese Lynch syndrome family: a pedigree study. J Zhejiang Univ Sci B 2019; 20 (01) 105-108
    CrossrefPubMedGoogle Scholar
  • 63 Te Paske IBAW, Mensenkamp AR, Neveling K, Hoogerbrugge N, Ligtenberg MJL, De Voer RM. ERN-GENTURIS Lynch-Like Working Group. Noncoding aberrations in mismatch repair genes underlie a substantial part of the missing heritability in Lynch syndrome. Gastroenterology 2022; 163 (06) 1691-1694.e7
    CrossrefPubMedGoogle Scholar
  • 64 Yurgelun MB, Allen B, Kaldate RR. et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 2015; 149 (03) 604-13.e20
    CrossrefPubMedGoogle Scholar
  • 65 Espenschied CR, LaDuca H, Li S, McFarland R, Gau CL, Hampel H. Multigene panel testing provides a new perspective on Lynch syndrome. J Clin Oncol 2017; 35 (22) 2568-2575
    CrossrefPubMedGoogle Scholar
  • 66 Pearlman R, Frankel WL, Swanson B. et al; Ohio Colorectal Cancer Prevention Initiative Study Group. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 2017; 3 (04) 464-471
    CrossrefPubMedGoogle Scholar